Leanbio
Albert Font Ingles serves as the Chief Executive Officer and Chief Operating Officer at LeanBioPro since September 2015. Prior to this role, Albert was the Head of Upstream Process Development and Bioanalytical Method Development Group Leader at 3P Biopharmaceuticals from September 2013 to August 2015. Earlier experience includes a position as a Bioprocess Development Scientist at Bioingenium, s.l. from February 2008 to July 2013 and roles as a Graduate Research Assistant at both Universitat Autònoma de Barcelona and the Institute of Applied Microbiology of Vienna. Albert holds a Master's degree in Advanced Biotechnology with a focus on Industrial Biotechnology, a Ph.D. in Biotechnology, as well as Bachelor's degrees in Biochemistry and Biotechnology, all from Universitat Autònoma de Barcelona.
This person is not in any teams
This person is not in any offices
Leanbio
Leanbio is a market oriented CDMO that develops and manufactures biopharmaceutical products as New biological entities and Biosimilars, applying “Lean bioproduction” through tailored quality by design and ICH compliant approach in order to maximize project success, minimize time to market, costs and risks. Leanbio follows a knowledge-based strategy, applying cutting edge technological platforms and working altogether with customers through the different stages of development across project lifecycle: Platform development Specific development Process characterization Scale-up Manufacture Leanbio covers full value chain of services in the development and manufacture of biotherapeutics from gene to vial.